Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 2/20 | 0.36 |
| ▸ | USP9X | Q93008 | 1/20 | 0.35 |
| ▸ | DRD2 | P14416 | 1/20 | 0.34 |
| ▸ | DRD1 | P21728 | 1/20 | 0.34 |
| ▸ | USP1 | O94782 | 1/20 | 0.34 |
| ▸ | WDR48 | Q8TAF3 | 1/20 | 0.34 |
| ▸ | HTR6 | P50406 | 1/20 | 0.33 |
| ▸ | ACACB | O00763 | 1/20 | 0.32 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.32 |
| ▸ | RBP4 | P02753 | 2/20 | 0.32 |
| ▸ | GUCY1B2 | O75343 | 5/20 | 0.32 |
| ▸ | GUCY1A2 | P33402 | 5/20 | 0.32 |
| ▸ | GUCY1A1 | Q02108 | 5/20 | 0.32 |
| ▸ | GUCY1B1 | Q02153 | 5/20 | 0.32 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.31 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21263682 | 0.87 | USP9X (0.42) | EGFRUSP9XUSP1WDR48TRPV1 | |
| SCHEMBL18368403 | 0.84 | DRD2 (0.36) | DRD2HTR6TRPV1 | |
| SCHEMBL18376163 | 0.81 | GUCY1B2 (0.38) | DRD2DRD1HTR6GUCY1B2GUCY1A2 | |
| SCHEMBL23066177 | 0.78 | C5AR1 (0.37) | DRD2DRD1HTR6RBP4GUCY1B2 | |
| SCHEMBL12680738 | 0.74 | MAOA (0.53) | DRD2DRD1HTR6 | |
| SCHEMBL12681592 | 0.73 | ACACB (0.36) | ACACBTRPV1HSP90AA1HSP90AB1 | |
| SCHEMBL18609104 | 0.73 | GABRA1 (0.38) | ACACBTRPV1HSP90AA1HSP90AB1 | |
| SCHEMBL19755625 | 0.73 | HRH3 (0.36) | HTR6ACACBTRPV1 | |
| SCHEMBL18368357 | 0.72 | EGFR (0.38) | EGFR | |
| SCHEMBL24192292 | 0.71 | TRPV1 (0.34) | DRD2HTR6ACACBTRPV1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11827662-B2 | Cot modulators and methods of use thereof | GILEAD SCIENCES, INC. (US) | 2023-11-28 | — | — | US | disclosed |
| US-11827662-B2 | Cot modulators and methods of use thereof | GILEAD SCIENCES, INC. (US) | 2023-11-28 | — | — | US | disclosed |
| US-20230002407-A1 | COT MODULATORS AND METHODS OF USE THEREOF | GILEAD SCIENCES, INC. | 2023-01-05 | — | — | US | disclosed |
| US-11066414-B2 | Cot modulators and methods of use thereof | GILEAD SCIENCES, INC. (US) | 2021-07-20 | — | — | US | disclosed |
| US-10947259-B2 | Cot modulators and methods of use thereof | GILEAD SCIENCES, INC. (US) | 2021-03-16 | — | — | US | disclosed |
| US-20200392170-A1 | COT MODULATORS AND METHODS OF USE THEREOF | GILEAD SCIENCES, INC. | 2020-12-17 | — | — | US | disclosed |
| US-20200123172-A1 | COT MODULATORS AND METHODS OF USE THEREOF | GILEAD SCIENCES, INC. | 2020-04-23 | — | — | US | disclosed |
| US-9878995-B2 | Cot modulators and methods of use thereof | GILEAD SCIENCES, INC. (US) | 2018-01-30 | — | — | US | disclosed |
| US-20170152240-A1 | COT MODULATORS AND METHODS OF USE THEREOF | GILEAD SCIENCES, INC. | 2017-06-01 | — | — | US | disclosed |
| US-20170008905-A1 | COT MODULATORS AND METHODS OF USE THEREOF | GILEAD SCIENCES, INC. | 2017-01-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200392170-A1 | COT MODULATORS AND METHODS OF USE THEREOF | BRDT, THRB, HCCS | EGFR 1147/4885USP9X 2967/4885DRD2 4763/4885 |
| US-10947259-B2 | Cot modulators and methods of use thereof | BRDT, THRB, HCCS | EGFR 1147/4885USP9X 2967/4885DRD2 4763/4885 |
| US-20230002407-A1 | COT MODULATORS AND METHODS OF USE THEREOF | BRDT, THRB, HCCS | EGFR 1147/4885USP9X 2967/4885DRD2 4763/4885 |
| US-20200123172-A1 | COT MODULATORS AND METHODS OF USE THEREOF | BRDT, THRB, HCCS | EGFR 1147/4885USP9X 2967/4885DRD2 4763/4885 |
| US-20170152240-A1 | COT MODULATORS AND METHODS OF USE THEREOF | BRDT, THRB, HCCS | EGFR 1147/4885USP9X 2967/4885DRD2 4763/4885 |
| US-11066414-B2 | Cot modulators and methods of use thereof | BRDT, THRB, HCCS | EGFR 1147/4885USP9X 2967/4885DRD2 4763/4885 |
| US-20170008905-A1 | COT MODULATORS AND METHODS OF USE THEREOF | BRDT, THRB, HCCS | EGFR 1147/4885USP9X 2967/4885DRD2 4763/4885 |
| US-11827662-B2 | Cot modulators and methods of use thereof | BRDT, THRB, HCCS | EGFR 1147/4885USP9X 2967/4885DRD2 4763/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.